{
    "trials": [
        {
            "id": "NCT00343668",
            "title": "A Phase II Study of S-1 and Irinotecan Combination Chemotherapy in Patients With Advanced Gastric Cancer as a First-Line Therapy",
            "symPyJSON": {
                "type": "and",
                "operands": [
                    {
                        "type": "and",
                        "operands": [
                            {
                                "type": "variable",
                                "value": "Pathologically proven unresectable adenocarcinoma of stomach"
                            },
                            {
                                "type": "variable",
                                "value": "With uni-dimensionally measurable disease"
                            },
                            {
                                "type": "variable",
                                "value": "Age 18 to 70 years old"
                            },
                            {
                                "type": "variable",
                                "value": "Estimated life expectancy of more than 3 months"
                            },
                            {
                                "type": "variable",
                                "value": "ECOG performance status of 2 or lower"
                            },
                            {
                                "type": "variable",
                                "value": "Adequate bone marrow function"
                            },
                            {
                                "type": "variable",
                                "value": "Adequate kidney function"
                            },
                            {
                                "type": "variable",
                                "value": "Adequate liver function"
                            },
                            {
                                "type": "variable",
                                "value": "No prior chemotherapy but prior adjuvant chemotherapy finished at least 6 months before enrollment was allowed"
                            },
                            {
                                "type": "variable",
                                "value": "No prior radiation therapy for at least 4 weeks before enrollment in the study"
                            },
                            {
                                "type": "variable",
                                "value": "Must have minimum age of 18 Years"
                            },
                            {
                                "type": "variable",
                                "value": "Must have maximum age of 70 Years"
                            }
                        ]
                    },
                    {
                        "type": "not",
                        "operands": [
                            {
                                "type": "or",
                                "operands": [
                                    {
                                        "type": "variable",
                                        "value": "Other tumor type than adenocarcinoma"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Central nervous system (CNS) metastases or prior radiation for CNS metastases"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Gastric outlet obstruction or intestinal obstruction"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Evidence of gastrointestinal bleeding"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "The patient has bony lesions as the sole evaluable disease"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Past or concurrent history of neoplasm other than stomach cancer, except for curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix uteri"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Pregnant or lactating women, women of childbearing potential not employing adequate contraception"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Other serious illness or medical conditions"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Unstable cardiac disease despite treatment, myocardial infarction within 6 months prior to study entry"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "History of significant neurologic or psychiatric disorders including dementia or seizures"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Active uncontrolled infection"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Other serious underlying medical conditions which could impair the ability of the patient to participate in the study"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Concomitant administration of any other experimental drug under investigation, or concomitant chemotherapy, hormonal therapy, or immunotherapy"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Concomitant drug medication; The following drugs cause drug interaction with S-1: Warfarin or phenprocoumon - increase bleeding tendency; Phenytoin - increase blood concentration; Sorivudine - inhibit DPD -> increase toxicity according to fluoropyrimidine; Allopurinol - decrease activity of S-1"
                                    }
                                ]
                            }
                        ]
                    }
                ]
            },
            "symPyExpression": "'N/A'"
        },
        {
            "id": "NCT00312429",
            "title": "Cord Blood Transplantation in Adult Recipients",
            "symPyJSON": {
                "type": "and",
                "operands": [
                    {
                        "type": "variable",
                        "value": "Diagnosis reviewed at transplant center and confirmed to fit the criterion for high risk blood disease or cancer, as defined for the study"
                    },
                    {
                        "type": "variable",
                        "value": "Estimated life expectancy of at least 6 weeks following study entry"
                    },
                    {
                        "type": "variable",
                        "value": "Cancer and Leukemia Group B (CALGB) performance status less than or equal to 2"
                    },
                    {
                        "type": "variable",
                        "value": "White blood cell count, platelet, hematocrit, tuberculosis, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, creatinine, and HIV test results reviewed by transplant center"
                    },
                    {
                        "type": "variable",
                        "value": "Multiple gated acquisition (MUGA), echocardiogram, cardiac MRI, and/or pulmonary function tests (PFT) performed and reviewed by transplant center"
                    },
                    {
                        "type": "and",
                        "operands": [
                            {
                                "type": "not",
                                "operands": [
                                    {
                                        "type": "variable",
                                        "value": "individual has an ejection fraction and diffusing capacity [DLCO] of less than 40%"
                                    }
                                ]
                            },
                            {
                                "type": "not",
                                "operands": [
                                    {
                                        "type": "variable",
                                        "value": "individual has severe heart or lung disease at the initiation of therapy without the appropriate cardiology or pulmonary consultations"
                                    }
                                ]
                            }
                        ]
                    },
                    {
                        "type": "variable",
                        "value": "Sufficient number of umbilical cord blood units available for transplantation"
                    },
                    {
                        "type": "variable",
                        "value": "If female, willing to use contraception throughout the study"
                    },
                    {
                        "type": "variable",
                        "value": "Must have minimum age of 18 Years"
                    },
                    {
                        "type": "variable",
                        "value": "Must have maximum age of 70 Years"
                    },
                    {
                        "type": "not",
                        "operands": [
                            {
                                "type": "or",
                                "operands": [
                                    {
                                        "type": "variable",
                                        "value": "Undergoing Interleukin-2 (IL-2) therapy within 8 weeks of study entry"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Diagnosed with a medical or psychiatric illness that may interfere with study participation"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Pregnant"
                                    }
                                ]
                            }
                        ]
                    }
                ]
            },
            "symPyExpression": "And(Symbol('Cancer_and_Leukemia_Group_B_(CALGB)_performance_status_less_than_or_equal_to_2'), Symbol('Diagnosis_reviewed_at_transplant_center_and_confirmed_to_fit_the_criterion_for_high_risk_blood_disease_or_cancer__as_defined_for_the_study'), Symbol('Estimated_life_expectancy_of_at_least_6_weeks_following_study_entry'), Symbol('If_female__willing_to_use_contraception_throughout_the_study'), Symbol('Multiple_gated_acquisition_(MUGA)__echocardiogram__cardiac_MRI__and/or_pulmonary_function_tests_(PFT)_performed_and_reviewed_by_transplant_center'), Symbol('Must_have_maximum_age_of_70_Years'), Symbol('Must_have_minimum_age_of_18_Years'), Symbol('Sufficient_number_of_umbilical_cord_blood_units_available_for_transplantation'), Symbol('White_blood_cell_count__platelet__hematocrit__tuberculosis__aspartate_aminotransferase_(AST)__alanine_aminotransferase_(ALT)__alkaline_phosphatase__creatinine__and_HIV_test_results_reviewed_by_transplant_center'), Not(Symbol('individual_has_an_ejection_fraction_and_diffusing_capacity_[DLCO]_of_less_than_40%')), Not(Symbol('individual_has_severe_heart_or_lung_disease_at_the_initiation_of_therapy_without_the_appropriate_cardiology_or_pulmonary_consultations')), Not(Or(Symbol('Diagnosed_with_a_medical_or_psychiatric_illness_that_may_interfere_with_study_participation'), Symbol('Pregnant'), Symbol('Undergoing_Interleukin-2_(IL-2)_therapy_within_8_weeks_of_study_entry'))))"
        },
        {
            "id": "NCT00319748",
            "title": "Phase II Study of 852A Administered Subcutaneously in Patients With Metastatic Refractory Breast, Ovarian, Endometrial and Cervical Cancers",
            "symPyJSON": {
                "type": "and",
                "operands": [
                    {
                        "type": "and",
                        "operands": [
                            {
                                "type": "or",
                                "operands": [
                                    {
                                        "type": "variable",
                                        "value": "Breast - Karnofsky score > 50"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Ovarian, endometrial or cervical - Gynecologic Oncology Group (GOG) performance score \u22642"
                                    }
                                ]
                            },
                            {
                                "type": "variable",
                                "value": "If female and of childbearing potential, are willing to use adequate contraception (hormonal, barrier method, abstinence) prior to study entry and for the duration of study participation"
                            },
                            {
                                "type": "variable",
                                "value": "Normal organ function within 14 days of study entry"
                            },
                            {
                                "type": "or",
                                "operands": [
                                    {
                                        "type": "variable",
                                        "value": "Diagnosis of metastatic breast cancer (BR)"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Diagnosis of metastatic ovarian cancer (OV)"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Diagnosis of metastatic endometrial cancer (EM)"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Diagnosis of metastatic cervical cancer (CX)"
                                    }
                                ]
                            },
                            {
                                "type": "and",
                                "operands": [
                                    {
                                        "type": "variable",
                                        "value": "Measurable metastatic disease (>1cm) in at least one site other than bone-only"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Progression on or failure to respond to at least one previous chemotherapy regimen for metastatic disease"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Progression on prior therapy with a hormonal agent if estrogen receptor or progesterone receptor positive, and/or with trastuzumab if HER2-neu positive"
                                    }
                                ]
                            },
                            {
                                "type": "and",
                                "operands": [
                                    {
                                        "type": "variable",
                                        "value": "Measurable metastatic disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST)"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Primary tumor must have been diagnosed histologically as either epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Subjects must have failed at least two previous chemotherapy regimens"
                                    }
                                ]
                            },
                            {
                                "type": "and",
                                "operands": [
                                    {
                                        "type": "variable",
                                        "value": "Measurable metastatic disease"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Histologically proven recurrent or persistent endometrial cancer that is not amenable to curative treatment with surgery and/or radiation therapy AND has failed 2 previous treatment regimens"
                                    }
                                ]
                            },
                            {
                                "type": "and",
                                "operands": [
                                    {
                                        "type": "variable",
                                        "value": "Measurable metastatic disease"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Histologically proven recurrent or persistent squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix that is not amenable to curative treatment with surgery and/or radiation therapy AND has failed 2 previous treatment regimens"
                                    }
                                ]
                            },
                            {
                                "type": "variable",
                                "value": "Must have minimum age of 18 Years"
                            }
                        ]
                    },
                    {
                        "type": "not",
                        "operands": [
                            {
                                "type": "or",
                                "operands": [
                                    {
                                        "type": "variable",
                                        "value": "Systemic corticosteroids (oral or injectable) within 7 days of first dose of 852A"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Investigational drugs/agents within 14 days of first dose of 852A"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Immunosuppressive therapy, including cytotoxic agents within 14 days of first dose of 852A"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Drugs known to induce QT interval prolongation and/or induce Torsades de pointes unless best available drug required to treat life-threatening conditions"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Radiotherapy within 3 weeks of the first dose of 852A"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Hematopoietic cell transplantation within 4 weeks of first dose of 852A"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Evidence of active infection within 3 days of first dose of 852A"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Active fungal infection or pulmonary infiltrates"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Cardiac ischemia, cardiac arrhythmias or congestive heart failure uncontrolled by medication"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "History of, or clinical evidence of, a condition which, in the opinion of the investigator, could confound the results of the study or put the subject at undue risk"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Uncontrolled intercurrent or chronic illness"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Active autoimmune disease requiring immunosuppressive therapy within 30 days"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Active coagulation disorder not controlled with medication"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Pregnant or lactating"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Concurrent malignancy (if in remission, at least 5 years disease free) except for localized (in-situ) disease, basal carcinomas and cutaneous squamous cell carcinomas that have been adequately treated"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Any history of brain metastases or any other active central nervous system (CNS) disease"
                                    }
                                ]
                            }
                        ]
                    }
                ]
            },
            "symPyExpression": "And(Symbol('Histologically_proven_recurrent_or_persistent_endometrial_cancer_that_is_not_amenable_to_curative_treatment_with_surgery_and/or_radiation_therapy_AND_has_failed_2_previous_treatment_regimens'), Symbol('Histologically_proven_recurrent_or_persistent_squamous_cell_carcinoma__adenosquamous_carcinoma__or_adenocarcinoma_of_the_cervix_that_is_not_amenable_to_curative_treatment_with_surgery_and/or_radiation_therapy_AND_has_failed_2_previous_treatment_regimens'), Symbol('If_female_and_of_childbearing_potential__are_willing_to_use_adequate_contraception_(hormonal__barrier_method__abstinence)_prior_to_study_entry_and_for_the_duration_of_study_participation'), Symbol('Measurable_metastatic_disease'), Symbol('Measurable_metastatic_disease_(>1cm)_in_at_least_one_site_other_than_bone-only'), Symbol('Measurable_metastatic_disease_as_defined_by_Response_Evaluation_Criteria_in_Solid_Tumors_(RECIST)'), Symbol('Must_have_minimum_age_of_18_Years'), Symbol('Normal_organ_function_within_14_days_of_study_entry'), Symbol('Primary_tumor_must_have_been_diagnosed_histologically_as_either_epithelial_ovarian_cancer__fallopian_tube_cancer__or_primary_peritoneal_cancer'), Symbol('Progression_on_or_failure_to_respond_to_at_least_one_previous_chemotherapy_regimen_for_metastatic_disease'), Symbol('Progression_on_prior_therapy_with_a_hormonal_agent_if_estrogen_receptor_or_progesterone_receptor_positive__and/or_with_trastuzumab_if_HER2-neu_positive'), Symbol('Subjects_must_have_failed_at_least_two_previous_chemotherapy_regimens'), Or(Symbol('Breast_-_Karnofsky_score_>_50'), Symbol('Ovarian__endometrial_or_cervical_-_Gynecologic_Oncology_Group_(GOG)_performance_score_\u22642')), Or(Symbol('Diagnosis_of_metastatic_breast_cancer_(BR)'), Symbol('Diagnosis_of_metastatic_cervical_cancer_(CX)'), Symbol('Diagnosis_of_metastatic_endometrial_cancer_(EM)'), Symbol('Diagnosis_of_metastatic_ovarian_cancer_(OV)')), Not(Or(Symbol('Active_autoimmune_disease_requiring_immunosuppressive_therapy_within_30_days'), Symbol('Active_coagulation_disorder_not_controlled_with_medication'), Symbol('Active_fungal_infection_or_pulmonary_infiltrates'), Symbol('Any_history_of_brain_metastases_or_any_other_active_central_nervous_system_(CNS)_disease'), Symbol('Cardiac_ischemia__cardiac_arrhythmias_or_congestive_heart_failure_uncontrolled_by_medication'), Symbol('Concurrent_malignancy_(if_in_remission__at_least_5_years_disease_free)_except_for_localized_(in-situ)_disease__basal_carcinomas_and_cutaneous_squamous_cell_carcinomas_that_have_been_adequately_treated'), Symbol('Drugs_known_to_induce_QT_interval_prolongation_and/or_induce_Torsades_de_pointes_unless_best_available_drug_required_to_treat_life-threatening_conditions'), Symbol('Evidence_of_active_infection_within_3_days_of_first_dose_of_852A'), Symbol('Hematopoietic_cell_transplantation_within_4_weeks_of_first_dose_of_852A'), Symbol('History_of__or_clinical_evidence_of__a_condition_which__in_the_opinion_of_the_investigator__could_confound_the_results_of_the_study_or_put_the_subject_at_undue_risk'), Symbol('Immunosuppressive_therapy__including_cytotoxic_agents_within_14_days_of_first_dose_of_852A'), Symbol('Investigational_drugs/agents_within_14_days_of_first_dose_of_852A'), Symbol('Pregnant_or_lactating'), Symbol('Radiotherapy_within_3_weeks_of_the_first_dose_of_852A'), Symbol('Systemic_corticosteroids_(oral_or_injectable)_within_7_days_of_first_dose_of_852A'), Symbol('Uncontrolled_intercurrent_or_chronic_illness'))))"
        },
        {
            "id": "NCT00356148",
            "title": "Phase IV Study of Determining the Efficacy of Ampicillin/Sulbactam Combination as Antibiotic Prophylaxis During Breast Cancer Surgery in Patients With a Body Mass Index (BMI) Over 25.",
            "symPyJSON": {
                "type": "and",
                "operands": [
                    {
                        "type": "and",
                        "operands": [
                            {
                                "type": "variable",
                                "value": "Women at any age with early stage breast cancer (stage I-II)"
                            },
                            {
                                "type": "variable",
                                "value": "American Society of Anesthesiologists (ASA) score of I-II"
                            },
                            {
                                "type": "variable",
                                "value": "FEMALE"
                            },
                            {
                                "type": "variable",
                                "value": "minimum age of 18 Years"
                            }
                        ]
                    },
                    {
                        "type": "not",
                        "operands": [
                            {
                                "type": "or",
                                "operands": [
                                    {
                                        "type": "variable",
                                        "value": "Ductal carcinoma in situ (DCIS; stage 0 cancer)"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Advanced or distant metastatic stage"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Receiving any neoadjuvant therapy"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "History of receiving any antibiotics within prior 3 months"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "History of immunodeficiency"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Having a remote infection"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "History of reaction to study antibiotics"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Denial of signing the consent form"
                                    }
                                ]
                            }
                        ]
                    }
                ]
            },
            "symPyExpression": "And(Symbol('American_Society_of_Anesthesiologists_(ASA)_score_of_I-II'), Symbol('FEMALE'), Symbol('Women_at_any_age_with_early_stage_breast_cancer_(stage_I-II)'), Symbol('minimum_age_of_18_Years'), Not(Or(Symbol('Advanced_or_distant_metastatic_stage'), Symbol('Denial_of_signing_the_consent_form'), Symbol('Ductal_carcinoma_in_situ_(DCIS;_stage_0_cancer)'), Symbol('Having_a_remote_infection'), Symbol('History_of_immunodeficiency'), Symbol('History_of_reaction_to_study_antibiotics'), Symbol('History_of_receiving_any_antibiotics_within_prior_3_months'), Symbol('Receiving_any_neoadjuvant_therapy'))))"
        },
        {
            "id": "NCT00344318",
            "title": "To Assess the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Pneumococcal Conjugate Vaccine Compared to Prevenar\u2122, Co-administered With DTPw-HBV/Hib & OPV or IPV Vaccines as a 3-dose Primary Immunization Course During the First 6 Months of Age",
            "symPyJSON": "Invalid JSON",
            "symPyExpression": "'N/A'"
        },
        {
            "id": "NCT00317148",
            "title": "Phase II-III Placebo-Controlled, Study to Evaluate the Effects of DHEA on Vasomotor Symptoms (Hot Flashes) in Postmenopausal Women",
            "symPyJSON": {
                "type": "and",
                "operands": [
                    {
                        "type": "and",
                        "operands": [
                            {
                                "type": "variable",
                                "value": "Healthy postmenopausal women"
                            },
                            {
                                "type": "variable",
                                "value": "50 or more moderate to severe hot flushes"
                            }
                        ]
                    },
                    {
                        "type": "and",
                        "operands": [
                            {
                                "type": "variable",
                                "value": "Women between 40 to 70 years of age"
                            },
                            {
                                "type": "variable",
                                "value": "Must be FEMALE"
                            },
                            {
                                "type": "variable",
                                "value": "Must have minimum age of 40 Years"
                            },
                            {
                                "type": "variable",
                                "value": "Must have maximum age of 70 Years"
                            }
                        ]
                    },
                    {
                        "type": "not",
                        "operands": [
                            {
                                "type": "or",
                                "operands": [
                                    {
                                        "type": "variable",
                                        "value": "Body mass index (BMI) of 35 kg/m2 or more"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Significant metabolic and endocrine diseases"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Diagnosis of cancer"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Use of steroids or drugs that interfere with the metabolism of estrogen"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Use of any systemic estrogen, progestin, or DHEA in the eight weeks prior to randomization"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Use of alternative therapies or natural products to treat postmenopausal symptoms in the four weeks prior to randomization"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Palpable fibroids or uterine prolapse: Grade 2 or 3"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "Cigarette smoking"
                                    }
                                ]
                            }
                        ]
                    }
                ]
            },
            "symPyExpression": "'N/A'"
        },
        {
            "id": "NCT00305097",
            "title": "Effects of Caffeinated and Decaffeinated Coffee on Body Weight and Glucose Tolerance",
            "symPyJSON": "Invalid JSON",
            "symPyExpression": "'N/A'"
        },
        {
            "id": "NCT00351611",
            "title": "PROSPECTIVE RANDOMIZED 12-WEEK CONTROLLED STUDY OF VISUAL FIELD CHANGE IN SUBJECTS WITH PARTIAL SEIZURES RECEIVING PREGABALIN OR PLACEBO",
            "symPyJSON": "Invalid JSON",
            "symPyExpression": "'N/A'"
        },
        {
            "id": "NCT00279552",
            "title": "Can Recombinant Human Intrinsic Factor Be Used for Evaluation of the Vitamin B12 Absorption?",
            "symPyJSON": "Invalid JSON",
            "symPyExpression": "'N/A'"
        },
        {
            "id": "NCT00324363",
            "title": "Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and Metformin",
            "symPyJSON": "Invalid JSON",
            "symPyExpression": "'N/A'"
        }
    ]
}